Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie acquisition signals confidence in small-cap biotech sector's growth potential
02:54pm, Tuesday, 26'th Mar 2024
AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of nove
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
11:06am, Tuesday, 26'th Mar 2024
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
06:51pm, Monday, 25'th Mar 2024
AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
12:46pm, Monday, 25'th Mar 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:06am, Monday, 25'th Mar 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
08:39am, Monday, 25'th Mar 2024
AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
12:46am, Sunday, 24'th Mar 2024
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tier
AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval
05:17pm, Friday, 22'nd Mar 2024
The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments conside
US FDA grants full approval to AbbVie's ovarian cancer therapy
02:38pm, Friday, 22'nd Mar 2024
The U.S. Food and Drug Administration (FDA) said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for adult patients with a type of ovarian and rela
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
06:51pm, Tuesday, 19'th Mar 2024
In the most recent trading session, AbbVie (ABBV) closed at $179.66, indicating a +0.66% shift from the previous trading day.
2 Top Dividend Stocks to Buy Hand Over Fist
08:15am, Sunday, 17'th Mar 2024
AbbVie and Gilead Sciences haven't been recording excellent financial results lately. But both drugmakers have solid lineups and pipelines that should allow them to recover.
AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)
02:09pm, Thursday, 14'th Mar 2024
AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)
Why AbbVie (ABBV) Dipped More Than Broader Market Today
06:51pm, Wednesday, 13'th Mar 2024
In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.
February's Dividend Portfolio Update Sets New Record - 100 Holdings, 19 Strategic Buys
08:10am, Wednesday, 13'th Mar 2024
US stocks climbed higher in February with the DJIA adding 0.4% and the S&P closing in on the 5,000-point mark.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:05am, Tuesday, 12'th Mar 2024
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
